A rational approach to the management of recurrent or persistent ovarian carcinoma

Clinical Obstetrics and Gynecology
Tate Thigpen

Abstract

Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.

References

Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanW Hoskins
Feb 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F Ozols
Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Sep 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E BajettaC Carnaghi
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseH D Homesley
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M MuggiaJ M Small
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah SchragUNKNOWN ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays
Jan 6, 2006·The New England Journal of Medicine·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Nov 17, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-M FerreroE Pujade-Lauraine
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert A BurgerJoel I Sorosky
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen A CannistraWilliam McGuire
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriella FerrandinaGiovanni Scambia
Jul 8, 2008·Human Pathology·C Blake GilksUNKNOWN Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency
Jul 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Russell J SchilderBarbara C Vanderhyden
Oct 22, 2008·Gynecologic Oncology·Robert E BristowDennis S Chi
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A BookmanLawrence M Roth
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula A MatulonisRichard T Penson
Feb 16, 2010·The American Journal of Surgical Pathology·Robert J Kurman, Ie-Ming Shih
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Aug 5, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Helen J MackayUNKNOWN Gynecologic Cancer InterGroup
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela MateiMichael J Birrer
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Tate ThigpenUNKNOWN Gynecologic Cancer InterGroup
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group

❮ Previous
Next ❯

Citations

Jun 4, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sohita Dhillon
Jul 6, 2014·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·E C GrendysT J Herzog
Jun 21, 2014·Expert Opinion on Drug Delivery·Wen Jen Lin, Li Ting Kao
Apr 30, 2015·Acta Obstetricia Et Gynecologica Scandinavica·Alex RabinovichWalter H Gotlieb
May 22, 2016·Gynecologic Oncology·Katrina SlaughterKathleen M Moore
Mar 23, 2017·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·Yakup BozkayaNurullah Zengin
Sep 25, 2017·Oncotarget·Ping LiuHong Ni
Oct 6, 2017·Oncotarget·Yvonne AnderssonKjersti Flatmark
Jan 22, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Natpat Jansaka, Prapaporn Suprasert
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne LeijenJan H M Schellens
May 26, 2017·The Journal of Obstetrics and Gynaecology Research·Yuki YamadaHiroshi Kobayashi
Mar 8, 2020·Journal of Cancer Research and Clinical Oncology·Mayumi Kobayashi KatoKenji Tamura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Advances in Therapy
Florian HeitzAndreas du Bois
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Tate ThigpenGynecologic Cancer InterGroup
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gordon J S Rustin
© 2022 Meta ULC. All rights reserved